Next Article in Journal
Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms
Next Article in Special Issue
An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities
Previous Article in Journal
A Focused Review on Cognitive Improvement by the Genus Salvia L. (Sage)—From Ethnopharmacology to Clinical Evidence
Previous Article in Special Issue
Biological Evaluation of Valeriana Extracts from Argentina with Potent Cholinesterase Inhibition for the Treatment of Neurodegenerative Disorders and Their Comorbidities—The Case of Valeriana carnosa Sm. (Caprifoliaceae) Studied in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 2
10.3390/ph16020172
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study

by
Neto-Honorius Houngbedji
1,
Šárka Štěpánková
2,
Václav Pflégr
1,
Katarína Svrčková
2,
Markéta Švarcová
1,
Jarmila Vinšová
1 and
Martin Krátký
1,*
1
Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
2
Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(2), 172; https://doi.org/10.3390/ph16020172
Submission received: 31 December 2022 / Revised: 16 January 2023 / Accepted: 19 January 2023 / Published: 24 January 2023
(This article belongs to the Special Issue Advances in Acetylcholinesterase and Butyrylcholinesterase Inhibitors)
Browse Figures
Versions Notes

Abstract

:
On the basis of previous reports, novel 2-benzoylhydrazine-1-carboxamides were designed as potential inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Inhibitors of these enzymes have many clinical applications. 2-(Substituted benzoyl)hydrazine-1-carboxamides decorated with N-methyl or tridecyl were prepared with three methods from commercially available or self-prepared hydrazides and isocyanates. For methyl derivatives, N-succinimidyl N-methylcarbamate was used or methyl isocyanate was prepared via Curtius rearrangement. Tridecyl isocyanate was synthesized again via Curtius rearrangement or from triphosgene and tridecylamine. The compounds were evaluated for the inhibition of AChE and BChE using Ellman’s spectrophotometric method. Most of the derivatives showed the dual inhibition of both enzymes with IC50 values of 44–100 µM for AChE and from 22 µM for BChE. In general, the carboxamides inhibited AChE more strongly. A large number of the compounds showed better or quite comparable inhibition of cholinesterases in vitro than that of the drug rivastigmine. Molecular docking was performed to investigate the possible conformation of the compounds and their interactions with target enzymes. In both AChE and BChE, the compounds occupied the enzyme active cavity, and, especially in the case of BChE, the compounds were placed in close proximity to the catalytic triad.

Graphical Abstract

1. Introduction

2-Acylhydrazine-1-carboxamides are a group of compounds with interesting and potentially useful biological properties utilized in drug design. They have been reported as antimycobacterial [1,2], antibacterial [3,4], antifungal [4], anticancer [5], anticonvulsant [6] and anti-inflammatory [3] agents. Importantly, hydrazine-1-carboxamides have also been reported as inhibitors of cholinesterases [2,7].
Krátký et al. [2] reported a series of N-alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides (I, Figure 1; n-alkyl chain R from C1 to C18) as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). All hydrazinecarboxamides exhibited dual inhibition of both AChE and BChE, with IC50 values of 27.0–106.8 μM and 58.0–277.5 μM, respectively. In the case of AChE inhibition, the IC50 values of the most potent inhibitors were lower than those of the established drug rivastigmine. The most potent and also selective AChE inhibitors were found to be N-tridecyl/pentadecyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides. N-Methyl analog was identified as the third most potent AChE inhibitor along with significant inhibition of BChE. Molecular docking studies suggest that these compounds may act as non-covalent inhibitors located near the catalytic triad.
Given together with the fact that AChE and/or BChE inhibitors are a cornerstone of therapy for neurodegenerative diseases, including Alzheimer’s disease, myasthenia gravis [8] and other diseases, we designed and conducted a follow-up study of potential cholinesterase inhibitors based on the most potent N-methyl/tridecyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides. The changes performed included the type of substituent on the benzene ring and its position, as well as other types of amide linkers (Figure 1).

2. Results and Discussion

2.1. Design

Based on the successful hydrazinecarboxamide scaffold (I, Figure 1; compounds P1 and P2), we decided to retain N-methyl and N-tridecyl chains. N-Tridecyl was selected and preferred over N-pentadecyl moiety. Both of these alkyls exhibit similar activity, but tridecyl derivatives are less lipophilic and, based on in silico calculations, some pentadecyl derivatives would exceed the logP value of 5. However, even among our compounds, there are tridecyl derivatives with higher logP values.
Focusing on the benzene ring, first we replaced the 4-CF3 group using diverse substituents (series 1) with different electronic (+I, −I, +M, −M), steric (small, bulkier, planar), lipophilic and hydrogen bonding properties. We included ethers (OCF3: 1a, 1b; OCH3: 1u, 1v; OPh: 1w, 1x), all halogens (1c–1j), nitro compounds (1k, 1l), nitriles (1m, 1n), alkyls (Me: 1o, 1p; tert-butyl: 1q, 1r), phenyl (1s, 1t), dimethylamino (1y, 1z), hydroxy (1aa, 1bb) and sulfonamido (1cc, 1dd) moieties, as well as unsubstituted benzene (1ee, 1ff) for comparison.
Based on the results of this first series, we designed series 2 covering the positional isomers of the most potent AChE inhibitors (P1, P2 → 2a–2d) and BChE inhibitors (4-NO2 group: 1l → 2e–2h; 4-bromine: 1h → 2i–2l).
The last issue for modification was the linker connecting the 4-(trifluoromethyl)phenyl scaffold to the hydrazinecarboxamide (series 3). The C=O group was replaced by sulfonyl (3c, 3d), or one methylene group was inserted between CO and the benzene ring (3a, 3b).

2.2. Synthesis

The most common method for the preparation of 2-benzoylhydrazine-1-carboxamides and their analogs with modified linkers is the reaction of corresponding arylhydrazides with isocyanates.
The hydrazides that we used were commercially available or prepared in-house (Scheme 1; 4-iodobenzohydrazide, [1,1’-biphenyl]-4-carbohydrazide, 4-phenoxybenzohydrazide, 4-(trifluoromethoxy)benzohydrazide, 2- and 3-(trifluoromethyl)benzohydrazides, 4-(hydrazinecarbonyl)benzenesulfonamide, 4-cyanobenzohydrazide, as well as hydrazides with modified linkers, 2-phenylacetohydrazide and 4-(trifluoromethyl)benzenesulfonylhydrazide). Their syntheses started from free acids, which were almost quantitatively converted to methyl ester via Fischer esterification (with sulfuric acid as a catalyst). The esters were reacted under reflux with an excess of hydrazine hydrate to give corresponding hydrazides. Alternatively, when available, substituted benzoyl chloride was converted to methyl ester using methanol in the presence of triethylamine as a tertiary base.
Methyl isocyanate and tridecyl isocyanate are not routinely commercially available. Due to the notorious toxicity of methyl isocyanate [9], N-methylated hydrazinecarboxamides were initially prepared by reacting hydrazides with an excess of N-succinimidyl N-methylcarbamate (also known as “methyl isocyanate substitute”) in the presence of N-ethyl-N,N-diisopropylamine (DIPEA) as a non-nucleophilic tertiary base (method A; Scheme 2) [2]. Tridecyl isocyanate, as a compound with an odd number of carbons in the alkyl chain, was firstly prepared in situ from tridecylamine using triphosgene in the presence of triethylamine under a nitrogen atmosphere. Then, it was reacted with hydrazide to afford target N-tridecylhydrazinecarboxamides (method B; Scheme 2). N-Alkyl-2-{2-[4-(trifluoromethyl)phenyl]acetyl}hydrazine-1-carboxamides 3a and 3b were also obtained in this way.
However, both these methods gave inconsistent and generally lower yields (Table 1). Therefore, we decided to prepare both isocyanates via the Curtius rearrangement from commercially available chlorides (acetyl and myristoyl chloride), which were converted to azides via reaction with sodium azide in toluene and were then gently heated to induce rearrangement and thus the formation of isocyanates [10]. The crude isocyanate was immediately used for a subsequent reaction with hydrazides (method C; Scheme 3). This procedure led to significantly increased yields (Table 1); lower yields were in the case of nitro- and sulfamoylbenzohydrazide derivatives.
Compounds 1–3 (Table 2) were characterized by NMR (1H, 13C) and IR spectra and melting points. The purity was verified additionally by elemental analysis.

2.3. Inhibition of Acetylcholinesterase and Butyrylcholinesterase

Hydrazinecarboxamides 1–3 were examined in vitro for their potential to inhibit the function of AChE (obtained from electric eel) and BChE from equine serum using Ellman’s spectrophotometric method (Table 2). The activities are expressed as IC50 values, i.e., concentrations leading to 50% inhibition of enzymatic activity. Based on the IC50 values for AChE and BChE, we calculated selectivity indexes (SI) that quantified the selectivity for each cholinesterase. SI is the ratio of IC50 for BChE/IC50 for AChE. Values less than 1 indicate the preferential inhibition of BChE, whereas values above 1 mean stronger inhibition of AChE. For comparison, the clinically used drug rivastigmine, a dual inhibitor of AChE and BChE, was employed.
Most of derivatives 1–3 produced a duality of inhibition of both cholinesterases, although with different potencies. Only 1i together with some derivatives from series 2, i.e., the positional isomers of the most potent inhibitors from series 1, did not significantly inhibit BChE (IC50 >500 μM; 2- and 3-nitro compounds 2e and 2h, 2- and 3-brominated analogs 2j–2l). AChE was inhibited with a narrower range of IC50 values (44.08–100.08 µM) with the most potent inhibitors being 2-(4-chlorobenzoyl)-N-methylhydrazine-1-carboxamide 1e and 2-(3-bromobenzoyl)-N-tridecylhydrazine-1-carboxamide 2j. In contrast, the lowest activity was associated with 2-(4-methylbenzoyl)-N-tridecylhydrazine-1-carboxamide 1p. The replacement of the 4-CF3 group with any substituent (series 1) or its positional isomers (series 2) did not result in improved AChE inhibition. Consistently, better inhibition was associated with electron-withdrawing 4-NO2 and 4-CN groups (1k–1n) and 2-/3-Br (2i-2l). In series 1, less lipophilic N-methyl derivatives are predominantly more potent AChE inhibitors than tridecyl compounds; the exceptions are derivatives with large aromatic 4-phenyl(oxy) moieties (1s, 1t and 1w, 1x) and sulfonamides 1cc and 1dd. Focusing on positional isomers (series 2), the activity dropped (CF3: P1 and P2 vs. 2a-2d; NO2: 1k and 1l vs. 2e–2g). For bromine, the situation was not uniform. For N-methyl analog 1g, both 3- and 2-Br isomers (2i and 2k) did not provide an increase in activity, but among tridecylated hydrazinecarboxamides, this modification resulted in lower IC50 values (1h vs. 2j and 2l). Focusing on linker modifications (series 3), the replacement of C=O with both CH2CO and SO2 was detrimental (P1, P2 vs. 3a–3d), favoring original benzohydrazides.
In the case of BChE inhibition, the results are quite different. This hydrolase was inhibited in a wider concentration range (IC50 of 22.31–>500 µM). Based on the IC50 values, hydrazinecarboxamides can be divided into three groups: (1) highly active inhibitors (IC50 values of 22.31–88.68 µM) comprising N-tridecyl derivatives of 4-nitro- (1l), 4-bromo- (1h), 4-phenyl- (1t), 4-tert-butyl- (1r) and 4-chlorobenzohydrazide (1f); (2) the largest group of compounds with moderate activity (IC50 values of 125.23–483.50 µM); and (3) inactive compounds with IC50 values above 500 μM (1i, 2e, 2h and 2j–2k). The positional isomers clearly led to a reduction in or abolition of the activity (series 1 vs. series 2), as did a linker modification (series 1 vs. series 3). Only changes in the 4-substitution of benzohydrazide showed a positive effect on the inhibition of BChE, which mainly favored the nitro group (1k, 1l). For most N-methyl vs. tridecyl pairs in series 1, a longer alkyl was beneficial (up to 13.3× for 1g vs. 1h).
Concerning the selectivity to both enzymes (SI in Table 2), most of the derivatives were preferential AChE inhibitors (SI values of 1.9–>11.3). The most selective inhibitors of AChE were derivatives of 2- and 3-bromobenzohydrazide (2j–2l), 2-nitrobenzohydrazide (2h) and sulfonamide 3d with SI > 8.4. Three tridecylated compounds were balanced inhibitors of both enzymes (1f, 1r and 1t), and only two hydrazinecarboxamides inhibited BChE more strongly than AChE: N-tridecyl derivatives of 4-bromo- and 4-nitrobenzohydrazide 1h and 1l. Comparing parent molecules P, series 1 and 2, the positional isomers of the 4-substituted benzohydrazides were more selective to AChE.
When compounds 1, 2 and 3 were compared with rivastigmine, some of them exhibited lower IC50 values than this drug, namely 1e, 1g, 2i and 2j, and many of them showed comparable activity (1a, 1c, 1d, 1k-1o, 1q, 1t, 1u, 1x, 2a, 2c, 2h, 2k, 2l and 3d). Three N-tridecyl derivatives were better inhibitors of BChE than rivastigmine (1h, 1l and 1t). In this respect, two compounds generally showed better inhibitory properties in vitro than those of rivastigmine: 2-(4-nitrobenzoyl)-N-tridecylhydrazine-1-carboxamide 1l and 2-(4-phenylbenzoyl)-N-tridecylhydrazine-1-carboxamide 1t, which are more potent BChE inhibitors and are also slightly better AChE inhibitors. Keeping in mind the design of the study to improve the activity of N-methyl/tridecyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides P1 and P2 [2], the goal for the inhibition of AChE was not achieved, but for BChE, many tridecyl derivatives presented here were superior to the parent compound P2 (1b, 1f, 1h, 1j, 1l, 1r, 1t, 1z, 1bb, 1dd, 1ff and 2f), even 12.4× for 4-nitrobenzohydrazide derivative 1l.

2.4. Molecular Docking

The active site of AChE has been investigated thoroughly by AChE mutant studies and X-ray crystallography of the enzyme bound to various ligands [11,12,13].
The hydrolysis of acetylcholine takes place at the bottom of a deep and narrow gorge and is directly mediated by three amino acids, Ser203, His447 and Glu334, forming the so-called catalytic triad. However, several important regions, responsible for the navigation of the substrate to the gorge and its suitable orientation in the cavity, have been described. The so-called peripheral anionic site, formed mostly by aromatic residues (Trp286, Tyr124, Tyr72 and Tyr341), is important for the formation of cation–π interactions with cationic substrates, which then proceed toward a choline-binding pocket (Trp86 and Tyr337) and acyl-binding pocket (Phe295, Phe297, and Trp236), which is believed to be responsible for accommodating the acyl part of the substrate after hydrolysis takes place [14].
A comparison of the active sites of AChE and BChE revealed that most differences in the substrate’s specificity originate from the fact that many aromatic residues present in the AChE active site are missing in BChE, being replaced by smaller hydrophobic residues. Out of 10 aromatic residues interacting with ligands in AChE, only 4 remain in BChE: Tyr332 (Tyr341 in AChE) in the peripheral site and Trp82, Phe329 and Trp231 (Trp86, Phe338 and Trp236 in AChE) in the active site [14]. This, among other things, allows more spacious ligands to enter the cavity.
To better understand the binding mode of the prepared compounds in AChE and BChE, a molecular modeling study was performed.
The top scoring docking pose of two most potent AChE inhibitors in the series, 1e and 2j, gave a similar orientation of these compounds in the cavity of the enzyme despite quite large differences in their structures (Figure 2). The substituted aryl moiety showed stacking with Trp86, and the 2-acylhydrazine-1-carboxamide linker was stabilized in its position by several H-bond interactions (namely with Asp74, Tyr124, Ser125 and Tyr31). In the case of compound 2j, the long tridecyl tail was heading out toward the entrance of the cavity, where several hydrophobic amino acid residues were (Leu76, Phe338 and Trp286), which further contributed to the additional stabilization of the ligand in the enzyme.
The conformation of 1l (together with 1h, being two of the most potent inhibitors of BChE in all series) is shown in Figure 3. The acylhydrazine-1-carboxamide linker is in close proximity to the catalytic active site, able to form H-bond interactions with amino acid residues of the catalytic triad. The tridecyl moiety of both ligands was buried deeper in the cavity of BChE when compared to AChE surrounded by hydrophobic amino acids Phe329 and Ala328. This corresponded to the general assumption that the cavity of BChE is more spacious than that of AChE. Nevertheless, both enzymes were capable of accommodateing the tridecyl moiety without any difficulties.

3. Materials and Methods

3.1. Chemistry

3.1.1. General

All chemicals were purchased from Merck KGaA (Darmstadt, Germany), Acros Organics B.V.B.A. (Geel, Belgium), Penta Chemicals Unlimited (Prague, Czech Republic) and Avantor (Stříbrná Skalice, Czech Republic) and were used as received. The progress of reactions was monitored via thin-layer chromatography (TLC). Plates were coated with 0.2 mm Merck 60 F254 silica gel (Merck, Darmstadt, Germany) and were visualized via UV light (254 and 366 nm). Alternatively, ALUGRAM SIL G/UV254 aluminum plates (Macherey-Nagel GmbH, Düren, Germany) coated with a 0.2 mm silica gel layer (60A, with a fluorescent indicator for 254 nm) were used (method C). Avantor Silica Gel with a particle size of 40–60 µm was used for column chromatography without prior activation. Melting points were recorded using a Büchi B-560 apparatus (BÜCHI Labortechnik AG, Flawil, Switzerland), and they were without correction.
The structures of both known and new compounds were determined via 1H NMR and 13C NMR spectroscopy. NMR spectra were measured in a dimethyl sulfoxide (DMSO-d6) solution at an ambient temperature with a JNM-ECZ 600R (600 MHz for 1H and 151 MHz for 13C; JEOL, Tokio, Japan) or a Varian VNMR S500 instrument (500 MHz for 1H and 126 MHz for 13C; Varian Comp. Palo Alto, CA, USA). The chemical shifts (δ) are reported in parts per million (ppm) and are indirectly related to tetramethylsilane via residual signals of the solvent (2.50 for 1H and 39.51 for 13C spectra). Coupling constants (J) are given in Hz. Infrared spectra were recorded via a Nicolet 6700 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) in the range of 600–4000 cm−1. The attenuated total reflectance technique (ATR) on a germanium crystal was used. Elemental analysis was performed on a Vario MICRO Cube Elemental Analyzer (Elementar Analysensysteme, Hanau, Germany). Calculated and found values are given as percentages; all the calculated and experimental values were within ±0.4%.
Lipophilicity (expressed as consensus log Po/w) was determined in silico using a freely available tool SwissADME (http://www.swissadme.ch/index.php, accessed 5 December 2022).

3.1.2. Synthesis

Synthesis of Parent Hydrazides

Hydrazide precursors for final compounds 1–3 were obtained commercially or prepared in-house. Their synthesis involved the hydrazinolysis of methyl esters in boiling ethanol. The esters were prepared from commercially available acyl chlorides and methanol in the presence of an excess of triethylamine. Alternatively, free acid was esterified with methanol using a catalytic amount of sulfuric acid under reflux.
We previously reported on the preparation of 4-iodobenzohydrazide [15], and we also used the procedure for 2-phenylacetohydrazide [16], [1,1’-biphenyl]-4-carbohydrazide [17], 4-phenoxybenzohydrazide [18], 4-(trifluoromethoxy)benzohydrazide [19], 3-(trifluoromethyl)benzohydrazide [20], 2-(trifluoromethyl)benzohydrazide [21], 4-(hydrazinecarbonyl)benzenesulfonamide [22], 4-cyanobenzohydrazide [23] and 4-(trifluoromethyl)benzenesulfonylhydrazide [24].
The spectral and physical characterizations (NMR, IR and melting points) of these precursor compounds were in accordance with literature. Their purity was checked via elemental analysis.

Synthesis of Hydrazine-1-carboxamides

Method A
Substituted benzohydrazide (1.0 mmol) was dissolved in acetonitrile (5 mL) and mixed with N,N-diisopropylethylamine (DIPEA; 2.0 mmol, 348 µL) followed by N-succinimidyl N-methylcarbamate (1.5 mmol; 258.2 mg). The reaction mixture was stirred at room temperature for 24 h, the formed precipitate was filtered off, it was washed with cold water and diethyl ether, and it was crystallized from ethyl acetate.
Method B
Triphosgene (0.4 mol, 118.7 mg) was dissolved in anhydrous dichloromethane (DCM; 5 mL) under a nitrogen atmosphere. Then, tridecylamine (1.01 mmol; 201.4 mg) dissolved in anhydrous DCM (5 mL) was added dropwise. After 30 min of stirring at room temperature, triethylamine (2.1 mmol, 293 µL) was added. After an additional 30 min, substituted benzohydrazide (1.0 mmol) was added. The reaction mixture was stirred for 10 h at room temperature and was then evaporated to dryness, treated with water (10 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered off and evaporated to dryness to give the final product, which was crystallized from ethyl acetate.
Method C
Both alkyl isocyanates were prepared via the Curtius rearrangement from commercially available acyl chlorides according to the known method [10]. The crude isocyanate was used immediately for a subsequent reaction.
Then, 1 mmol of the appropriate benzohydrazide (benzenesulfonyl hydrazide) was dissolved/suspended in 10 mL of anhydrous acetonitrile and was heated to a boil under a nitrogen atmosphere, and then a 1.1 equivalent (1.1 mmol, as a solution in toluene) of alkyl isocyanate was added in one portion to the vigorously stirred reaction mixture. The reaction mixture was heated under reflux for one hour. The solvent was evaporated under reduced pressure. The crude product was purified via column chromatography on silica gel using gradient elution (pure DCM → mixture of DCM to CH3OH; 93:7 V/V). The reaction progress was monitored via TLC (DCM + CH3OH; 93:7 V/V).
N-Methyl-2-[4-(trifluoromethoxy)benzoyl]hydrazine-1-carboxamide 1a. White solid. Yield 91% (method C), mp 237–239 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.18 (1H, s, NH), 8.00–7.96 (2H, m, H2, H6), 7.88 (1H, s, NH), 7.46–7.43 (2H, m, H3, H5), 6.42 (1H, q, J = 4.5 Hz, NH-CH3), 2.54 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.75, 159.36, 151.08, 132.46, 130.50, 121.14, 120.91 (q, J = 255.0 Hz), 26.75. IR (ATR): 636, 760, 851, 912, 930, 988, 1016, 1064, 1165, 1211, 1252, 1344, 1424, 1502, 1544, 1584, 1609, 1644, 2890, 3074, 3274 cm−1. Elemental analysis for C10H10F3N3O3 (277.20); calculated: C, 43.33; H, 3.64; N, 15.16, found: C, 43.44; H, 3.77; N, 15.01. Rf: 0.46.
N-Tridecyl-2-[4-(trifluoromethoxy)benzoyl]hydrazine-1-carboxamide 1b. White needle-like solid. Yield 90% (method C), mp 200–201 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.98 (1H, s, NH), 7.97 (2H, d, J = 8.3 Hz, H2, H6), 7.63 (1H, s, NH), 7.39 (2H, d, J = 8.3 Hz, H3, H5), 6.24 (1H, t, J = 5.9 Hz, NH-CH2), 3.01 (2H, q, J = 6.6 Hz, NH-CH2), 1.38 (2H, p, J = 6.9 Hz, C2H2), 1.24–1.21 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.68, 158.66, 151.17, 132.65, 130.38, 121.43, 120.91 (q, J = 255.0 Hz), 31.75, 30.32, 29.50, 29.49, 29.48, 29.47, 29.46, 29.44, 29.29, 29.12, 26.84, 22.49, 14.25. IR (ATR): 627, 722, 862, 899, 922, 1015, 1059, 1168, 1204, 1266, 1339, 1470, 1490, 1549, 1591, 1640, 1668, 2853, 2921, 3278 cm−1. Elemental analysis for C22H34F3N3O3 (445.53); calculated: C, 59.31; H, 7.69; N, 9.43, found: C, 59.45; H, 7.61; N, 9.50. Rf: 0.46.
2-(4-Fluorobenzoyl)-N-methylhydrazine-1-carboxamide 1c. White solid. Yield 33% (method A), mp 221–223 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.13 (1H, s, NH), 7.99–7.93 (2H, m, H2, H6), 7.86 (1H, s, NH), 7.34–7.27 (2H, m, H3, H5), 6.43 (1H, q, J = 4.9 Hz, NH-CH3), 2.57 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.56, 164.29 (d, J = 249.0 Hz), 159.08, 130.46 (d, J = 9.1 Hz), 129.46 (d, J = 2.9 Hz), 115.42 (d, J = 21.8 Hz), 26.42. IR (ATR): 3309, 3070, 1665, 1644, 1603, 1581, 1542, 1494, 1341, 1299, 1254, 1230, 1163, 1100, 1010, 912, 848, 927, 813, 758, 650, 629 cm−1. Elemental analysis for C9H10FN3O2 (211.20); calculated: C, 51.18; H, 4.77; N, 19.90, found: C, 51.24; H, 4.70; N, 20.01.
2-(4-Fluorobenzoyl)-N-tridecylhydrazine-1-carboxamide 1d. White solid. Yield 25% (method B), mp 196–198 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.95 (1H, d, J = 2.0 Hz, NH), 7.94–7.90 (2H, m, H2, H6), 7.62 (1H, s, NH), 7.26–7.21 (2H, m, H3, H5), 6.26 (1H, t, J = 5.9 Hz, NH-CH2), 3.00 (2H, q, J = 6.6 Hz, NH-CH2), 1.38 (2H, p, J = 7.0 Hz, C2H2), 1.29–1.21 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 7.0 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.85, 164.67 (d, J = 249.1 Hz), 158.76, 130.72 (d, J = 9.1 Hz), 130.01, 115.66 (d, J = 21.9 Hz), 39.87, 31.77, 30.35, 29.52, 29.50, 29.48, 29.31, 29.15, 26.84, 22.52, 14.31. IR (ATR): 3303, 3073, 2922, 2850, 1660, 1638, 1605, 1568, 1501, 1465, 1339, 1300, 1279, 1258, 1232, 1164, 1068, 914, 849, 771, 755, 725, 642, 627 cm−1. Elemental analysis for C21H34FN3O2 (379.52); calculated: C, 66.46; H, 9.03; N, 11.07, found: C, 66.41; H, 9.10; N, 11.05.
2-(4-Chlorobenzoyl)-N-methylhydrazine-1-carboxamide 1e. White solid. Yield 59% (method A), mp 227–229 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.18 (1H, s, NH), 7.92–7.88 (3H, m, NH, H2, H6), 7.57–7.54 (2H, m, H3, H5), 6.44 (1H, q, J = 4.7 Hz, NH-CH3), 2.57 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.61, 159.02, 136.64, 131.74, 129.70, 128.56, 26.42. IR (ATR): 3318, 3253, 3063, 1663, 1642, 1597, 1574, 1543, 1487, 1424, 1340, 1252, 1095, 1010, 910, 895, 845, 759, 727, 700, 663, 651, 625, 608 cm−1. Elemental analysis for C9H10ClN3O2 (227.65); calculated: C, 47.49; H, 4.43; N, 18.46, found: C, 47.54; H, 4.40; N, 18.51.
2-(4-Chlorobenzoyl)-N-tridecylhydrazine-1-carboxamide 1f. White solid. Yield 26% (method B), mp 195–197 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.16 (1H, s, NH), 7.91–7.87 (2H, m, H2, H6), 7.80 (1H, s, NH), 7.56–7.53 (2H, m, H3, H5), 6.49 (1H, t, J = 6.0 Hz, NH-CH2), 2.99 (2H, q, J = 6.5 Hz, NH-CH2), 1.36 (2H, p, J = 6.9 Hz, C2H2), 1.23–1.15 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.8 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.54, 158.45, 136.64, 131.75, 129.67, 128.57, 39.41, 31.49, 30.04, 29.26, 29.21, 29.12, 29.03, 28.91, 27.13, 26.50, 22.29, 14.14. IR (ATR): 3309, 2952, 2919, 2850, 1663, 1637, 1599, 1580, 1540, 1486, 1469, 1338, 1279, 1261, 1092, 1012, 907, 844, 751, 720, 667, 636, 622, 606 cm−1. Elemental analysis for C21H34ClN3O2 (395.97); calculated: C, 63.70; H, 8.66; N, 10.61, found: C, 63.74; H, 8.50; N, 10.51.
2-(4-Bromobenzoyl)-N-methylhydrazine-1-carboxamide 1g. White solid. Yield 40% (method A), mp 225–227 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.18 (1H, s, NH), 7.89 (1H, s, NH), 7.84–7.81 (2H, m, H2, H6), 7.71–7.68 (2H, m, H3, H5), 6.44 (1H, q, J = 5.0 Hz, NH-CH3), 2.57 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.74, 159.00, 132.11, 131.50, 129.88, 125.58, 26.43. IR (ATR): 3287, 1683, 1665, 1637, 1589, 1558, 1536, 1482, 1419, 1342, 1315, 1277, 1254, 1176, 1108, 1072, 1008, 898, 847, 824, 759, 715 cm−1. Elemental analysis for C9H10BrN3O2 (272.10); calculated: C, 39.73; H, 3.70; N, 15.44, found: C, 39.74; H, 3.65; N, 15.51.
2-(4-Bromobenzoyl)-N-tridecylhydrazine-1-carboxamide 1h. White solid. Yield 34% (method B), mp 144–146 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.16 (1H, s, NH), 7.86–7.81 (3H, m, NH, H2, H6), 7.72–7.68 (2H, m, H3, H5), 6.49 (1H, t, J = 5.0 Hz, NH-CH2), 3.06 (2H, q, J = 6.5 Hz, NH-CH2), 1.36 (2H, p, J = 6.8 Hz, C2H2), 1.24–1.19 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.8 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.59, 158.38, 132.48, 131.47, 129.82, 127.34, 38.92, 31.46, 29.23, 29.19, 29.10, 29.00, 28.88, 28.69, 27.12, 26.48, 25.98, 22.26, 14.11. IR (ATR): 2954, 2919, 2849, 1663, 1637, 1595, 1521, 1496, 1468, 1398, 1377, 1340, 1263, 1147, 1121, 1074, 1010, 981, 943, 897, 841, 754, 721, 646, 632, 625, 612 cm−1. Elemental analysis for C21H34BrN3O2 (440.43); calculated: C, 57.27; H, 7.78; N, 9.54, found: C, 57.24; H, 7.75; N, 9.59.
2-(4-Iodobenzoyl)-N-methylhydrazine-1-carboxamide 1i. White solid. Yield 24% (method A), mp 238–240 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.16 (1H, s, NH), 7.89–7.83 (3H, m, NH, H2, H6), 7.70–7.64 (2H, m, H3, H5), 6.43 (1H, s, NH-CH3), 2.57 (3H, s, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.99, 158.99, 137.35, 132.41, 129.69, 99.51, 26.43. IR (ATR): 3286, 1664, 1638, 1586, 1558, 1538, 1480, 1418, 1343, 1310, 1276, 1253, 1173, 1107, 1064, 1005, 898, 845, 825, 754, 706, 651, 633 cm−1. Elemental analysis for C9H10IN3O2 (319.10); calculated: C, 33.88; H, 3.16; N, 13.17, found: C, 33.79; H, 3.15; N, 13.10.
2-(4-Iodobenzoyl)-N-tridecylhydrazine-1-carboxamide 1j. White solid. Yield 24% (method B), mp 190–193 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.12 (1H, s, NH), 7.90–7.83 (3H, m, NH, H2, H6), 7.52 (2H, d, J = 8.3 Hz, H3, H5), 6.47 (1H, t, J = 5.0 Hz, NH-CH2), 2.90 (2H, q, J = 6.6 Hz, NH-CH2), 1.31 (2H, p, J = 6.8 Hz, C2H2), 1.25–1.19 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 157.18, 154.85, 138.64, 127.46, 124.00, 99.23, 40.76, 31.83, 29.95, 29.59, 29.57, 29.55, 29.52, 29.27, 29.25, 29.07, 26.76, 22.63, 14.46. IR (ATR): 3340, 2956, 2919, 2850, 1691, 1613, 1583, 1536, 1479, 1463, 1398, 1351, 1332, 1284, 1263, 1247, 1198, 1144, 1076, 1033, 1006, 967, 938, 823, 720, 668, 639, 627, 612 cm−1. Elemental analysis for C21H34IN3O2 (487.43); calculated: C, 51.75; H, 7.03; N, 8.62, found: C, 51.84; H, 7.05; N, 8.59.
N-Methyl-2-(4-nitrobenzoyl)hydrazine-1-carboxamide 1k. Yellowish solid. Yield 39% (method A), mp 252–254 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.44 (1H, s, NH), 8.33 (2H, d, J = 8.7 Hz, H3, H5), 8.15–8.00 (3H, m, NH, H2, H6), 6.52 (1H, s, NH-CH3), 2.59 (3H, s, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.11, 158.88, 149.47, 138.73, 129.33, 123.67, 26.45. IR (ATR): 3283, 3070, 1670, 1635, 1604, 1582, 1547, 1519, 1490, 1419, 1341, 1318, 1258, 1190, 1171, 1107, 1014, 989, 904, 875, 850, 716, 680, 644, 609 cm−1. Elemental analysis for C9H10N4O4 (238.20); calculated: C, 45.38; H, 4.23; N, 23.52, found: C, 45.49; H, 4.15; N, 23.60.
2-(4-Nitrobenzoyl)-N-tridecylhydrazine-1-carboxamide 1l. Yellowish solid. Yield 30% (method B), mp 252–252 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.45 (1H, s, NH), 8.31 (2H, d, J = 8.8 Hz, H3, H5), 8.16–8.05 (3H, m, NH, H2, H6), 6.48 (1H, t, J = 5.0 Hz, NH-CH2), 2.71 (2H, q, J = 6.6 Hz, NH-CH2), 1.53 (2H, p, J = 6.8 Hz, C2H2), 1.24–1.19 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 7.0 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 164.33, 159.12, 150.04, 136.25, 129.64, 124.02, 38.90, 31.52, 29.29, 29.26, 29.24, 29.16, 29.07, 28.94, 28.77, 27.14, 26.08, 22.32, 14.18. IR (ATR): 3268, 2954, 2929, 2850, 1673, 1605, 1589, 1530, 1481, 1344, 1326, 1286, 1191, 1173, 1147, 1118, 1039, 1009, 882, 845, 717, 648, 624, 606 cm−1. Elemental analysis for C21H34N4O4 (406.53); calculated: C, 62.05; H, 8.43; N, 13.78, found: C, 62.04; H, 8.35; N, 15.69.
2-(4-Cyanobenzoyl)-N-methylhydrazine-1-carboxamide 1m. White solid. Yield 94% (method C), mp 209–210 °C (decomp.). 1H NMR (600 MHz, DMSO-D6) δ 10.31 (1H, s, NH), 8.01–7.98 (2H, m, H2, H6), 7.95–7.92 (3H, m, NH, H3, H5), 6.45 (1H, q, J = 4.4 Hz, NH-CH3), 2.54 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.62, 159.22, 137.38, 132.93, 128.97, 118.83, 114.52, 26.77. IR (ATR): 612, 760, 774, 859, 905, 991, 1018, 1172, 1259, 1312, 1338, 1424, 1496, 1541, 1586, 1641, 1669, 2230, 3297 cm−1. Elemental analysis for C10H10N4O2 (218.22); calculated: C, 55.04; H, 4.62; N, 25.68, found: C, 55.18; H, 4.74; N, 25.59. Rf: 0.27.
2-(4-Cyanobenzoyl)-N-tridecylhydrazine-1-carboxamide 1n. White solid. Yield 99% (method C), mp 206–208°C. 1H NMR (600 MHz, DMSO-D6) δ 10.22 (1H, s, NH), 7.99 (2H, d, J = 8.4 Hz, H2, H6), 7.92 (2H, d, J = 8.1 Hz, H3, H5), 7.76 (1H, s, NH), 6.37 (1H, t, J = 5.8 Hz, NH-CH2), 2.99 (2H, q, J = 6.6 Hz, NH-CH2), 1.36 (2H, p, J = 6.9 Hz, C2H2), 1.21–1.12 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.82 (3H, t, J = 7.0 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.51, 158.57, 137.50, 132.86, 128.92, 118.74, 114.54, 31.79, 30.34, 29.56, 29.55, 29.54, 29.52, 29.51, 29.50, 29.32, 29.18, 26.83, 22.56, 14.38. IR (ATR): 626, 650, 724, 757, 855, 912, 1016, 1060, 1245, 1258, 1339, 1465, 1489, 1544, 1586, 1638, 1667, 2851, 2922, 3271, 3307 cm−1. Elemental analysis for C22H34N4O2 (386.54); calculated: C, 68.36; H, 8.87; N, 14.49, found: C, 68.42; H, 8.99; N, 14.40. Rf: 0.45.
N-Methyl-2-(4-methylbenzoyl)hydrazine-1-carboxamide 1o. White solid. Yield 36% (method A), mp 193–195 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.01 (1H, s, NH), 7.83–7.87 (3H, m, NH, H2, H6), 7.27 (2H, d, J = 8.1 Hz, H3, H5), 6.38 (1H, q, J = 5.7 Hz, NH-CH3), 2.57 (3H, d, J = 4.6 Hz, NH-CH3), 2.35 (3H, s, Ph-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.49, 159.17, 144.27, 130.16, 128.96, 127.77, 26.44, 21.18. IR (ATR): 3310, 3254, 3063, 1666, 1644, 1613, 1575, 1541, 1505, 1420, 1337, 1255, 1191, 1126, 1108, 1016, 910, 840, 750, 701, 646, 634, 629 cm−1. Elemental analysis for C10H13N3O2 (207.23); calculated: C, 57.96; H, 6.32; N, 20.28, found: C, 57.99; H, 6.35; N, 20.30.
2-(4-Methylbenzoyl)-N-tridecylhydrazine-1-carboxamide 1p. White solid. Yield 22% (method B), mp 159–161 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.51 (1H, s, NH), 7.87–7.83 (3H, m, NH, H2, H6), 7.28–7.24 (2H, m, H3, H5), 6.48 (1H, t, J = 5.0 Hz, NH-CH2), 3.04 (2H, q, J = 6.6 Hz, NH-CH2), 2.36 (3H, s, Ph-CH3), 1.36 (2H, p, J = 6.8 Hz, C2H2), 1.26–1.19 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 7.0 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.35, 158.53, 141.66, 130.15, 128.93, 127.71, 39.10, 31.47, 30.03, 29.28, 29.24, 29.20, 29.17, 29.01, 28.88, 26.48, 22.26, 21.15, 14.11. IR (ATR): 3293, 2917, 2850, 1666, 1643, 1614, 1586, 1542, 1504, 1468, 1377, 1339, 1262, 1190, 1124, 1063, 1017, 912, 838, 746, 721, 655, 641, 625 cm−1. Elemental analysis for C22H37N3O2 (375.56); calculated: C, 70.36; H, 9.93; N, 11.19, found: C, 70.44; H, 10.00; N, 11.15.
2-[(4-(tert-Butyl)benzoyl]-N-methylhydrazine-1-carboxamide 1q. White solid. Yield 25% (method A), mp 180–182 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.02 (1H, s, NH), 7.85–7.81 (3H, m, NH, H2, H6), 7.50–7.47 (2H, m, H3, H5), 6.37 (1H, q, J = 4.7 Hz, NH-CH3), 2.57 (3H, d, J = 4.6 Hz, NH-CH3), 1.29 (9H, s, C-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.45, 159.19, 154.68, 130.20, 127.64, 125.22, 34.86, 31.13, 26.46. IR (ATR): 3353, 3221, 2963, 2906, 2870, 1682, 1655, 1611, 1573, 1519, 1463, 1408, 1366, 1297, 1286, 1196, 1163, 1113, 1079, 1019, 926, 890, 854, 839, 765, 705, 658, 623, 607 cm−1. Elemental analysis for C13H19N3O2 (249.31); calculated: C, 62.63; H, 7.68; N, 16.85, found: C, 62.59; H, 7.65; N, 16.90.
2-[(4-(tert-Butyl)benzoyl]-N-tridecylhydrazine-1-carboxamide 1r. White solid. Yield 39% (method B), mp 103–105 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.99 (1H, s, NH), 7.80–7.77 (2H, m, H2, H6), 7.75 (1H, s, NH), 7.48–7.45 (2H, m, H3, H5), 6.44 (1H, t, J = 5.8 Hz, NH-CH2), 2.98 (2H, q, J = 6.6 Hz, NH-CH2), 1.34 (2H, p, J = 6.6 Hz, C2H2), 1.28–1.19 (29H, m, C-CH3, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.82 (3H, t, J = 6.9 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.99, 159.05, 155.17, 130.32, 127.90, 125.59, 39.96, 31.76, 31.38, 29.51, 29.48, 29.46, 29.39, 29.27, 29.16, 28.98, 27.41, 26.73, 26.25, 22.57, 14.43. IR (ATR): 3356, 3258, 2955, 2920, 2851, 1702, 1628, 1610, 1544, 1500, 1468, 1364, 1333, 1268, 1258, 1240, 1123, 1016, 978, 895, 852, 788, 761, 721, 663, 652, 635, 616 cm−1. Elemental analysis for C25H43N3O2 (417.64); calculated: C, 71.90; H, 10.38; N, 10.06, found: C, 72.01; H, 10.40; N, 10.13.
N-Methyl-2-(4-phenylbenzoyl)hydrazine-1-carboxamide 1s. White solid. Yield 20% (method A), mp 172–174 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.12 (1H, s, NH), 7.96 (2H, d, J = 8.2 Hz, H2, H6), 7.85 (1H, s, NH), 7.75 (2H, d, J = 8.3 Hz, H3, H5), 7.70 (2H, d, J = 7.7 Hz, H2’, H6’), 7.46 (2H, t, J = 7.5 Hz, H3’, H5’), 7.37 (1H, t, J = 7.3 Hz, H4’), 6.40 (1H, q, J = 5.7 Hz, NH-CH3), 2.55 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 166.61, 159.49, 143.66, 139.65, 132.14, 129.59, 128.82, 128.66, 127.42, 126.99, 26.81. IR (ATR): 3411, 3209, 1706, 1680, 1650, 1637, 1609, 1561, 1485, 1413, 1329, 1240, 1207, 1130, 1105, 1006, 901, 857, 780, 744, 690, 661, 636, 609 cm−1. Elemental analysis for C15H15N3O2 (269.30); calculated: C, 66.90; H, 5.61; N, 15.60, found: C, 66.96; H, 5.55; N, 15.70.
2-(4-Phenylbenzoyl)-N-tridecylhydrazine-1-carboxamide 1t. White solid. Yield 84% (method B), mp 249–251 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.63 (1H, s, NH), 8.02 (2H, d, J = 8.2 Hz, H2, H6), 7.97 (1H, s, NH), 7.81 (2H, d, J = 8.2 Hz, H3, H5), 7.72 (2H, d, J = 7.8 Hz, H2’, H6’), 7.47 (2H, t, J = 7.7 Hz, H3’, H5’), 7.39 (1H, t, J = 7.5 Hz, H4’), 6.46 (1H, t, J = 5.0 Hz, NH-CH2), 2.69 (2H, q, J = 6.3 Hz, NH-CH2), 1.40 (2H, p, J = 6.8 Hz, C2H2), 1.24–1.17 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 166.06, 158.32, 144.77, 139.36, 129.74, 129.64, 129.02, 128.92, 127.51, 127.40, 39.24, 31.82, 29.59, 29.56, 29.54, 29.46, 29.36, 29.24, 29.07, 27.46, 26.39, 22.62, 14.48. IR (ATR): 2955, 2920, 2850, 1673, 1610, 1575, 1558, 1520, 1484, 1468, 1449, 1401, 1303, 1238, 1163, 1146, 1078, 1036, 1006, 852, 779, 742, 722, 698, 648, 631, 614 cm−1. Elemental analysis for C27H39N3O2 (437.63); calculated: C, 74.10; H, 8.98; N, 9.60, found: C, 74.17; H, 9.05; N, 9.55.
2-(4-Methoxybenzoyl)-N-methylhydrazine-1-carboxamide 1u. White solid. Yield 34% (method A), mp 171–173 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.95 (1H, s, NH), 7.88–7.85 (2H, m, H2, H6), 7.78 (1H, s, NH), 7.02–6.99 (2H, m, H3, H5), 6.37 (1H, q, J = 5.0 Hz, NH-CH3), 3.81 (3H, s, OCH3), 2.57 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.10, 162.05, 159.24, 129.63, 125.12, 113.67, 55.55, 26.43. IR (ATR): 3347, 3323, 3004, 2944, 1685, 1634, 1610, 1574, 1524, 1496, 1467, 1420, 1324, 1260, 1173, 1104, 1027, 980, 902, 840, 797, 767, 738, 700, 652, 624 cm−1. Elemental analysis for C10H13N3O3 (223.23); calculated: C, 53.81; H, 5.87; N, 18.82, found: C, 53.89; H, 5.85; N, 18.90.
2-(4-Methoxybenzoyl)-N-tridecylhydrazine-1-carboxamide 1v. White solid. Yield 27% (method B), mp 149–151 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.96 (1H, s, NH), 7.86 (2H, d, J = 8.9 Hz, H2, H6), 7.76 (1H, s, NH), 6.99 (2H, d, J = 8.9 Hz, H3, H5), 6.51 (1H, t, J = 5.0 Hz, NH-CH2), 3.80 (3H, s, OCH3), 2.98 (2H, q, J = 6.6 Hz, NH-CH2), 1.35 (2H, p, J = 6.8 Hz, C2H2), 1.25–1.19 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.9 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.99, 162.02, 158.67, 129.60, 125.15, 113.65, 55.55, 45.41, 39.96, 31.47, 30.05, 29.24, 29.20, 29.18, 29.02, 28.88, 26.51, 22.27, 14.13. IR (ATR): 3291, 1954, 2918, 2851, 1645, 1609, 1583, 1541, 1504, 1647, 1376, 1340, 1309, 1255, 1180, 1038, 912, 842, 763, 722, 656, 640, 625 cm−1. Elemental analysis for C22H37N3O3 (391.56); calculated: C, 67.49; H, 9.53; N, 10.73, found: C, 67.53; H, 9.46; N, 10.65.
N-Methyl-2-(4-phenoxybenzoyl)hydrazine-1-carboxamide 1w. White solid. Yield 88% (method C), mp 176–177 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.01 (1H, s, NH), 7.89–7.87 (2H, m, H2, H6), 7.80 (1H, s, NH), 7.44–7.37 (2H, m, H3’, H5’), 7.21–7.15 (1H, m, H4’), 7.07–7.03 (2H, m, H3, H5), 7.02–6.98 (2H, m, H2’, H6’), 6.36 (1H, q, J = 4.5 Hz, NH-CH3), 2.54 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 166.20, 160.33, 159.50, 156.11, 130.81, 130.36, 127.99, 124.90, 120.07, 117.87, 26.78. IR (ATR): 618, 658, 692, 717, 760, 873, 899, 980, 1078, 1102, 1170, 1238, 1319, 1410, 1487, 1527, 1566, 1642, 1663, 2837, 3016, 3262 cm−1. Elemental analysis for C15H15N3O3 (285.30); calculated: C, 63.15; H, 5.30; N, 14.73, found: C, 63.24; H, 5.20; N, 14.84. Rf: 0.36.
2-(4-Phenoxybenzoyl)-N-tridecylhydrazine-1-carboxamide 1x. White flakes. Yield 86% (method C), mp 127–129 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.00 (1H, s, NH), 7.88 (2H, d, J = 8.5 Hz, H2, H6), 7.71 (1H, s, NH), 7.41 (2H, t, J = 7.8 Hz, H3’, H5’), 7.18 (1H, t, J = 7.4 Hz, H4’), 7.05 (2H, d, J = 7.9 Hz, H3, H5), 7.00 (2H, d, J = 8.6 Hz, H2’, H6’), 6.39 (1H, t, J = 5.9 Hz, NH-CH2), 2.97 (2H, q, J = 6.6 Hz, NH-CH2), 1.34 (2H, p, J = 7.1 Hz, C2H2), 1.22–1.18 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.8 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 166.12, 160.32, 158.91, 156.10, 130.80, 130.32, 127.98, 124.89, 120.07, 117.86, 31.83, 30.41, 29.61, 29.59, 29.58, 29.57, 29.56, 29.55, 29.38, 29.25, 26.85, 22.63, 14.48. IR (ATR): 629, 692, 721, 749, 793, 848, 872, 900, 1072, 1168, 1200, 1245, 1257, 1309, 1469, 1491, 1548, 1573, 1589, 1647, 2849, 2920, 2954, 3286 cm−1. Elemental analysis for C27H39N3O3 (453.63); calculated: C, 71.49; H, 8.67; N, 9.26, found: C, 71.57; H, 8.60; N, 9.12. Rf: 0.48.
2-[4-(Dimethylamino)benzoyl]-N-methylhydrazine-1-carboxamide 1y. White solid. Yield 31% (method A), mp 201–203 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.74 (1H, s, NH), 7.78–7.73 (2H, m, H2, H6), 7.68 (1H, s, NH), 6.72–6.68 (2H, m, H3, H5), 6.32 (1H, q, J = 4.6 Hz, NH-CH3), 2.96 (6H, s, N-CH3), 2.56 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.57, 159.47, 152.57, 129.16, 119.38, 110.88, 39.86, 26.45. IR (ATR): 3365, 3273, 2945, 1677, 1659, 1602, 1537, 1511, 1443, 1402, 1377, 1335, 1289, 1239, 1201, 1169, 1130, 1070, 950, 917, 886, 831, 770, 703, 650 cm−1. Elemental analysis for C11H16N4O2 (236.28); calculated: C, 55.92; H, 6.83; N, 23.71, found: C, 55.98; H, 6.75; N, 23.80.
2-[4-(Dimethylamino)benzoyl]-N-tridecylhydrazine-1-carboxamide 1z. White solid. Yield 83% (method B), mp 148–150 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.74 (1H, s, NH), 7.77–7.73 (2H, m, H2, H6), 7.62 (1H, s, NH), 6.70 (2H, d, J = 9.0 Hz, H3, H5), 6.37 (1H, t, J = 5.0 Hz, NH-CH2), 2.98 (2H, q, J = 6.5 Hz, NH-CH2), 2.96 (6H, s, N-CH3), 1.36 (2H, p, J = 6.9 Hz, C2H2), 1.26–1.20 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.9 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.43, 158.85, 152.50, 129.10, 118.26, 110.89, 39.80, 38.94, 31.50, 30.09, 29.28, 29.24, 29.14, 29.05, 28.93, 27.15, 26.52, 22.30, 14.15. IR (ATR): 3367, 3280, 2950, 2918, 2849, 1685, 1636, 1609, 1543, 1516, 1469, 1445, 1375, 1340, 1329, 1261, 1240, 1212, 1174, 1071, 952, 902, 835, 766, 722, 656, 609 cm−1. Elemental analysis for C23H40N4O2 (404.60); calculated: C, 68.28; H, 9.97; N, 13.85, found: C, 68.34; H, 10.03; N, 13.78.
2-(4-Hydroxybenzoyl)-N-methylhydrazine-1-carboxamide 1aa. White solid. Yield 30% (method A), mp 234–235 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.04 (1H, s, OH), 9.85 (1H, s, NH), 7.78–7.72 (3H, m, NH, H2, H6), 6.82–7.78 (2H, m, H3, H5), 6.35 (1H, q, J = 4.7 Hz, NH-CH3), 2.56 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.32, 160.70, 159.33, 129.76, 123.56, 114.99, 26.44. IR (ATR): 3407, 3331, 3183, 1687, 1635, 1607, 1587, 1542, 1512, 1493, 1462, 1442, 1412, 1310, 1284, 1259, 1226, 1169, 1117, 1102, 976, 903, 844, 757, 688, 657, 634, 610 cm−1. Elemental analysis for C9H11N3O3 (209.21); calculated: C, 51.67; H, 5.30; N, 20.09, found: C, 51.64; H, 5.27; N, 20.01.
2-(4-Hydroxybenzoyl)-N-tridecylhydrazine-1-carboxamide 1bb. White solid. Yield 25% (method B), 146–148 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.43 (1H, s, OH), 9.83 (1H, s, NH), 7.99 (1H, s, NH), 7.82–7.79 (2H, m, H2, H6), 6.90–7.87 (2H, m, H3, H5), 6.42 (1H, t, J = 5.9 Hz, NH-CH2), 3.04 (2H, q, J = 6.4 Hz, NH-CH2), 1.37 (2H, p, J = 6.9 Hz, C2H2), 1.26–1.20 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.9 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.25, 160.78, 158.77, 129.70, 123.50, 115.01, 38.93, 31.53, 30.11, 29.31, 29.26, 29.08, 28.96, 28.78, 27.16, 26.55, 26.07, 22.33, 14.19. IR (ATR): 3392, 3197, 2955, 2919, 2850, 1660, 1639, 1613, 1582, 1501, 1468, 1378, 1327, 1291, 1270, 1246, 1172, 1074, 904, 847, 767, 721, 659, 652, 633 cm−1. Elemental analysis for C21H35N3O3 (377.53); calculated: C, 66.81; H, 9.34; N, 11.13, found: C, 66.75; H, 9.41; N, 11.02.
N-Methyl-2-(4-sulfamoylbenzoyl)hydrazine-1-carboxamide 1cc. White solid. Yield 72% (method C), mp 233–234 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.24 (1H, s, NH), 8.00 (2H, d, J = 8.2 Hz, H2, H6), 7.91 (1H, s, NH), 7.87 (2H, d, J = 8.3 Hz, H3, H5), 7.46 (2H, s, SO2NH2), 6.43 (2H, q, J = 4.6 Hz, NH-CH3), 2.54 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.99, 159.28, 147.16, 136.27, 128.82, 126.08, 26.79. IR (ATR): 904, 1015, 1074, 1098, 1120, 1162, 1187, 1291, 1314, 1416, 1473, 1541, 1567, 1647, 3100, 3241, 3360 cm−1. Elemental analysis for C9H12N4O4S (272.28); calculated: C, 39.70; H, 4.44; N, 20.58, found: C, 39.80; H, 4.44; N, 20.62. Rf: 0.12.
2-(4-Sulfamoylbenzoyl)-N-tridecylhydrazine-1-carboxamide 1dd. White solid. Yield 99% (method C), mp 116–118 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.01 (1H, s, NH), 7.98 (2H, d, J = 8.2 Hz, H2, H6), 7.88 (2H, d, J = 8.2 Hz, H3, H5), 7.67 (1H, s, NH), 7.28 (2H, s, SO2NH2), 6.25 (1H, t, J = 5.9 Hz, NH-CH2), 3.01 (2H, q, J = 6.6 Hz, NH-CH2), 1.38 (2H, p, J = 6.9 Hz, C2H2), 1.25–1.21 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.86, 158.58, 147.30, 136.46, 128.62, 126.10, 31.75, 30.34, 29.50, 29.49, 29.48, 29.47, 29.46, 29.45, 29.29, 29.12, 26.84, 22.50, 14.28. IR (ATR): 676, 717, 748, 767, 853, 860, 901, 1022, 1093, 1163, 1257, 1289, 1326, 1343, 1377, 1472, 1478, 1519, 1572, 1647, 1667, 2850, 2918, 2954, 3288 cm−1. Elemental analysis for C21H36N4O4S (440.60); calculated: C, 57.25; H, 8.24; N, 12.72, found: C, 57.33; H, 8.20; N, 12.80. Rf: 0.17.
2-Benzoyl-N-methylhydrazine-1-carboxamide 1ee. White solid. Yield 28% (method A), mp 165–168 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.10 (1H, s, NH), 7.91–7.86 (3H, m, NH, H2, H6), 7.57–7.53 (1H, m, H4), 7.49–7.45 (2H, m, H3, H5), 6.42 (2H, q, J = 4.7 Hz, NH-CH3), 2.58 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 166.58, 159.14, 132.96, 131.82, 128.46, 127.77, 26.45. IR (ATR): 3310, 3280, 3056, 1648, 1603, 1581, 1536, 1490, 1419, 1344, 1330, 1255, 1188, 1109, 1074, 1025, 982, 911, 804, 748, 684, 636, 616 cm−1. Elemental analysis for C9H11N3O2 (193.21); calculated: C, 55.95; H, 5.74; N, 21.75, found: C, 56.00; H, 5.84; N, 21.69.
2-Benzoyl-N-tridecylhydrazine-1-carboxamide 1ff. White solid. Yield 34% (method B), mp 129–131 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.11 (1H, s, NH), 7.83 (1H, s, NH), 7.65–7.61 (1H, m, H4), 7.56–7.51 (2H, m, H2, H6), 7.48–7.44 (2H, m, H3, H5), 6.53 (1H, t, J = 6.0 Hz, NH-CH2), 3.03 (2H, q, J = 6.5 Hz, NH-CH2), 1.36 (2H, p, J = 6.9 Hz, C2H2), 1.25–1.20 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.9 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.96, 158.55, 132.96, 131.78, 128.88, 127.96, 45.43, 31.50, 30.08, 29.27, 29.23, 29.14, 29.05, 28.92, 26.53, 26.04, 22.30, 14.16, 8.58. IR (ATR): 3300, 2948, 2918, 2849, 1668, 1645, 1604, 1582, 1540, 1500, 1469, 1343, 1330, 1260, 1189, 1124, 1069, 1017, 982, 912, 806, 747, 684, 638, 618 cm−1. Elemental analysis for C21H35N3O2 (361.53); calculated: C, 69.77; H, 9.76; N, 11.62, found: C, 69.84; H, 9.83; N, 11.69.
N-Methyl-2-[3-(trifluoromethyl)benzoyl]hydrazine-1-carboxamide 2a. White solid. Yield 21% (method A), mp 202–204 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.38 (1H, s, NH), 8.23 (1H, t, J = 1.9 Hz, H2), 8.19–8.16 (1H, m, H6), 7.96 (1H, s, NH), 7.93–7.90 (1H, m, H4), 7.73 (1H, t, J = 7.8 Hz, H5), 6.51 (1H, q, J = 4.5 Hz, NH-CH3), 2.58 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 164.99, 158.92, 134.16, 131.82, 129.76, 129.26 (q, J = 32.0 Hz), 128.19 (q, J = 3.8 Hz), 124.41 (q, J = 3.9 Hz), 124.18 (q, J = 272.3 Hz), 26.40. IR (ATR): 3235, 3049, 1655, 1617, 1581, 1548, 1488, 1421, 1348, 1326, 1312, 1288, 1259, 1220, 1163, 1116, 1075, 983, 923, 819, 800, 762, 698, 667, 649, 615 cm−1. Elemental analysis for C10H10F3N3O2 (261.20); calculated: C, 45.98; H, 3.86; N, 16.09, found: C, 46.07; H, 3.90; N, 16.08.
N-Tridecyl-2-[3-(trifluoromethyl)benzoyl]hydrazine-1-carboxamide 2b. White solid. Yield 95% (method C), mp 140–141 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.16 (1H, s, NH), 8.18 (1H, s, NH), 8.16–8.12 (1H, m, H2), 7.88–7.84 (1H, m, H6), 7.71–7.66 (2H, m, H4, H5), 6.29 (1H, t, J = 6.1 Hz, NH-CH2), 3.01 (2H, q, J = 6.6 Hz, NH-CH2), 1.38 (2H, p, J = 6.9 Hz, C2H2), 1.25–1.21 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 6.7 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.49, 158.62, 134.55, 132.05, 130.04, 129.73 (q, J = 31.8 Hz), 128.15 (q, J = 3.9 Hz), 124.55 (q, J = 272.3 Hz), 124.73 (q, J = 4.7 Hz), 31.75, 30.33, 29.49, 29.48, 29.47, 29.46, 29.45, 29.44, 29.29, 29.11, 26.83, 22.49, 14.25. IR (ATR): 663, 725, 817, 922, 1073, 1124, 1170, 1244, 1258, 1287, 1311, 1326, 1468, 1558, 1568, 1650, 1668, 1688, 2851, 2921, 3278 cm−1. Elemental analysis for C22H34F3N3O2 (429.53); calculated: C, 61.52; H, 7.98; N, 9.78, found: C, 61.67; H, 8.09; N, 9.88. Rf: 0.48.
N-Methyl-2-[2-(trifluoromethyl)benzoyl]hydrazine-1-carboxamide 2c. White solid. Yield 21% (method A), mp 196–198 °C. 1H NMR (500 MHz, DMSO-D6) δ 10.38 (1H, s, NH), 8.23 (1H, s, NH), 8.17 (1H, d, J = 7.9 Hz, H6), 7.96–7.91 (2H, m, H3, H4), 7.74 (1H, t, J = 7.8 Hz, H5), 6.51 (1H, q, J = 4.6 Hz, NH-CH3), 2.58 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (126 MHz, DMSO-D6) δ 165.24, 158.96, 133.92, 131.87, 129.89, 129.29 (q, J = 32.2 Hz), 128.35 (q, J = 3.8 Hz), 124.46 (q, J = 4.0 Hz), 124.15 (q, J = 272.2 Hz), 26.40. IR (ATR): 3369, 3253, 3050, 1654, 1617, 1582, 1548, 1421, 1348, 1326, 1313, 1259, 1220, 1163, 1116, 1075, 986, 923, 819, 801, 762, 698, 667, 649, 611 cm−1. Elemental analysis for C10H10F3N3O2 (261.20); calculated: C, 45.98; H, 3.86; N, 16.09, found: C, 46.02; H, 3.93; N, 16.12.
N-Tridecyl-2-[2-(trifluoromethyl)benzoyl]hydrazine-1-carboxamide 2d. White solid. Yield 92% (method C), mp 134–136 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.82 (1H, s, NH), 7.78–7.73 (2H, m, H3, H6), 7.72–7.68 (1H, m, H4), 7.66–7.61 (2H, m, NH, H5), 5.98 (1H, t, J = 5.8 Hz, NH-CH2), 3.03 (2H, q, J = 6.6 Hz, NH-CH2), 1.40 (2H, p, J = 7.0 Hz, C2H2), 1.26–1.23 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.83 (3H, t, J = 6.8 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 167.28, 158.31, 134.99, 132.72, 130.68, 129.74, 127.15 (q, J = 31.8 Hz), 126.77 (q, J = 4.2 Hz), 124.19 (q, J = 273.7 Hz), 31.75, 30.31, 29.50, 29.49, 29.48, 29.47, 29.46, 29.45, 29.28, 29.12, 26.82, 22.49, 14.26. IR (ATR): 665, 727, 765, 900, 1036, 1056, 1110, 1120, 1140, 1188, 1240, 1256, 1271, 1315, 1378, 1448, 1463, 1538, 1588, 1602, 1613, 1660, 2849, 2924, 2954, 3180 cm−1. Elemental analysis for C22H34F3N3O2 (429.53); calculated: C, 61.52; H, 7.98; N, 9.78, found: C, 61.49; H, 8.10; N, 9.84. Rf: 0.38.
N-Methyl-2-(3-nitrobenzoyl)hydrazine-1-carboxamide 2e. Pale yellow solid. Yield 33% (method A), mp 220–222 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.44 (1H, s, NH), 8.68 (1H, t, J = 2.0 Hz, H2), 8.38 (1H, dd, J = 8.2, 2.4 Hz, H4), 8.29–8.26 (1H, m, H6), 7.96 (1H, s, NH), 7.77 (1H, t, J = 8.0 Hz, H5), 6.50 (1H, s, NH-CH3), 2.55 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.02, 159.23, 148.23, 134.87, 134.52, 130.68, 126.75, 122.95, 26.76. IR (ATR): 3305, 3099, 2949, 1668, 1644, 1587, 1542, 1519, 1476, 1437, 1416, 1354, 1340, 1257, 1228, 1161, 1130, 1086, 985, 935, 827, 777, 726, 673, 652, 644, 606 cm−1. Elemental analysis for C9H10N4O4 (238.20); calculated: C, 45.38; H, 4.23; N, 23.52, found: C, 45.41; H, 4.30; N, 23.46.
2-(3-Nitrobenzoyl)-N-tridecylhydrazine-1-carboxamide 2f. Pale yellow solid. Yield 64% (method C), mp 146–147 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.40 (1H, s, NH), 8.67 (1H, t, J = 2.0 Hz, H2), 8.36 (1H, dd, J = 8.1, 2.3 Hz, H4), 8.27 (1H, dd, J = 8.00, 1.4 Hz, H6), 7.82 (1H, s, NH), 7.76 (1H, t, J = 8.0 Hz, H5), 6.46 (1H, t, J = 5.9 Hz, NH-CH2), 2.99 (2H, q, J = 6.6 Hz, NH-CH2), 1.36 (2H, p, J = 7.0 Hz, C2H2), 1.24–1.18 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.82 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 164.84, 158.60, 148.32, 135.01, 134.42, 130.64, 126.63, 122.88, 31.80, 30.38, 29.57, 29.56, 29.55, 29.54, 29.52, 29.50, 29.34, 29.20, 26.84, 22.58, 14.41. IR (ATR): 629, 720, 820, 924, 1084, 1238, 1256, 1346, 1467, 1482, 1526, 1539, 1583, 1566, 1613, 2850, 2925, 2955, 3223, 3351 cm−1. Elemental analysis for C21H34N4O4 (406.53); calculated: C, 62.05; H, 8.43; N, 13.78, found: C, 62.14; H, 8.31; N, 13.84. Rf: 0.48.
N-Methyl-2-(2-nitrobenzoyl)hydrazine-1-carboxamide 2g. Pale yellow solid. Yield 17% (method A), mp 200–202 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.50 (1H, s, NH), 8.09 (1H, d, J = 8.1 Hz, H3), 8.03 (1H, s, NH), 7.80 (1H, t, J = 7.5 Hz, H5), 7.71–7.64 (2H, m, H4, H6), 6.15 (1H, q, J = 4.6 Hz, NH-CH3), 2.53 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 164.92, 159.03, 143.84, 135.50, 133.28, 131.12, 129.80, 124.97, 26.78. IR (ATR): 3355, 3103, 2954, 1671, 1644, 1585, 1540, 1524, 1477, 1356, 1255, 1232, 1061, 901, 935, 827, 770, 729, 671, 649 cm−1. Elemental analysis for C9H10N4O4 (238.20); calculated: C, 45.38; H, 4.23; N, 23.52, found: C, 45.42; H, 4.17; N, 23.56.
2-(2-Nitrobenzoyl)-N-tridecylhydrazine-1-carboxamide 2h. Pale yellow solid. Yield 21% (method B), mp 148–150 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.21 (1H, s, NH), 8.03 (1H, d, J = 8.1 Hz, H3), 8.00 (1H, s, NH), 7.80 (1H, t, J = 7.5 Hz, H5), 7.73–7.67 (2H, m, H4, H6), 6.15 (1H, t, J = 5.8 Hz, NH-CH2), 3.00 (2H, q, J = 6.6 Hz, NH-CH2), 1.36 (2H, p, J = 6.8 Hz, C2H2), 1.24–1.18 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.84, 158.28, 147.70, 134.18, 131.86, 131.00, 130.19, 124.75, 39.61, 31.83, 30.33, 29.60, 26.59, 29.56, 29.55, 29.36, 29.30, 29.25, 26.82, 22.63, 14.48. IR (ATR): 3356, 3179, 2955, 2924, 2489, 1608, 1585, 1539, 1524, 1478, 1460, 1352, 1255, 1238, 1064, 901, 859, 786, 757, 728, 698, 666 cm−1. Elemental analysis for C21H34N4O4 (406.53); calculated: C, 62.05; H, 8.43; N, 13.78, found: C, 62.10; H, 8.41; N, 13.75.
2-(3-Bromobenzoyl)-N-methylhydrazine-1-carboxamide 2i. White solid. Yield 65% (method A), mp 190–192 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.18 (1H, s, NH), 8.04 (1H, t, J = 1.9 Hz, H2), 7.88–7.81 (2H, m, NH, H6), 7.74–7.71 (1H, m, H4), 7.42 (1H, t, J = 7.9 Hz, H5), 6.44 (1H, s, NH-CH3), 2.54 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.58, 159.31, 135.55, 134.87, 131.10, 130.86, 127.23, 122.12, 26.76. IR (ATR): 3289, 1670, 1646, 1588, 1532, 1489, 1470, 1416, 1337, 1261, 1224, 1072, 995, 920, 808, 752, 724, 678, 644, 631, 616 cm−1. Elemental analysis for C9H10BrN3O2 (277.10); calculated: C, 39.73; H, 3.70; N, 15.44, found: C, 39.74; H, 3.76; N, 15.51.
2-(3-Bromobenzoyl)-N-tridecylhydrazine-1-carboxamide 2j. White solid. Yield 43% (method B), mp 145–147 °C. 1H NMR (600 MHz, DMSO-D6) δ 10.16 (1H, s, NH), 8.03 (1H, s, H2), 7.83 (1H, d, J = 7.8 Hz, H6), 7.78 (1H, s, NH), 7.72 (1H, d, J = 8.0 Hz, H4), 7.41 (1H, t, J = 7.9 Hz, H5), 6.47 (1H, t, J = 5.9 Hz, NH-CH2), 2.96 (2H, q, J = 6.6 Hz, NH-CH2), 1.34 (2H, p, J = 6.8 Hz, C2H2), 1.26–1.21 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 165.45, 158.74, 135.54, 134.86, 131.10, 130.83, 127.18, 122.13, 39.73, 31.84, 30.40, 29.63, 29.61, 29.56, 29.54, 29.48, 29.38, 29.26, 26.84, 22.64, 14.48. IR (ATR): 3322, 3038, 2921, 2850, 1660, 1650, 1588, 1566, 1468, 1336, 1257, 1244, 1070, 997, 924, 901, 805, 724, 683, 659, 644, 632, 613 cm−1. Elemental analysis for C21H34BrN3O2 (440.43); calculated: C, 57.27; H, 7.78; N, 9.54, found: C, 57.24; H, 7.74; N, 9.59.
2-(2-Bromobenzoyl)-N-methylhydrazine-1-carboxamide 2k. White solid. Yield 20% (method A), mp 180–182 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.93 (1H, d, J = 2.1 Hz, NH), 8.01 (1H, d, J = 2.1 Hz, NH), 7.63 (1H, dd, J = 8.0, 1.8 Hz, H6), 7.52 (1H, dd, J = 7.8, 1.8 Hz, H3), 7.42 (1H, td, J = 7.8, 1.8 Hz, H4), 7.36 (1H, td, J = 7.8, 1.7 Hz, H5), 6.14 (1H, q, J = 4.6 Hz, NH-CH3), 2.58 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 167.64, 158.96, 137.33, 133.41, 132.00, 130.13, 127.99, 119.93, 26.84. IR (ATR): 3385, 3284, 3188, 3002, 1710, 1645, 1591, 1568, 1542, 1472, 1429, 1412, 1356, 1327, 1251, 1147, 1123, 1029, 972, 901, 772, 747, 724, 701, 663, 646, 628 cm−1. Elemental analysis for C9H10BrN3O2 (277.10); calculated: C, 39.73; H, 3.70; N, 15.44, found: C, 39.70; H, 3.72; N, 15.39.
2-(2-Bromobenzoyl)-N-tridecylhydrazine-1-carboxamide 2l. White solid. Yield 67% (method B), mp 120–121 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.96 (1H, d, J = 2.1 Hz, NH), 7.96 (1H, d, J = 2.1 Hz, NH), 7.67 (1H, d, J = 8.0, H6), 7.51 (1H, dd, J = 7.6, 1.8 Hz, H3), 7.46 (1H, td, J = 7.8, 1.8 Hz, H4), 7.39 (1H, td, J = 7.8, 1.9 Hz, H5), 6.20 (1H, t, J = 5.8 Hz, NH-CH2), 3.03 (2H, q, J = 6.6 Hz, NH-CH2), 1.42–1.36 (2H, m, C2H2), 1.28–1.20 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.85 (3H, t, J = 6.7 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 167.17, 157.97, 136.97, 133.01, 131.61, 129.67, 127.64, 119.51, 45.78, 31.46, 30.01, 29.26, 29.24, 29.21, 29.19, 29.00, 28.88, 26.48, 26.33, 22.26, 14.12. IR (ATR): 3354, 3201, 2954, 2924, 2849, 1607, 1591, 1573, 1591, 1541, 1478, 1467, 1456, 1257, 1237, 1223, 1027, 984, 899, 777, 756, 741, 724, 654, 636 cm−1. Elemental analysis for C21H34BrN3O2 (440.43); calculated: C, 57.27; H, 7.78; N, 9.54, found: C, 57.20; H, 7.80; N, 9.49.
N-Methyl-2-{2-[4-(trifluoromethyl)phenyl]acetyl}hydrazine-1-carboxamide 3a. White solid. Yield 50% (method A), mp 209–210 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.73 (1H, d, J = 2.0 Hz, NH), 7.76 (1H, d, J = 2.0 Hz, NH), 7.63 (2H, d, J = 8.1 Hz, H3, H5), 7.47 (2H, d, J = 7.9 Hz, H2, H6), 6.27 (1H, q, J = 4.9 Hz, NH-CH3), 3.52 (2H, s, CH2), 2.52 (3H, d, J = 4.5 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 169.92, 159.12, 141.18, 130.56, 127.78 (q, J = 31.9 Hz), 125.54 (q, J = 3.9 Hz), 124.93 (q, J = 273.6 Hz), 42.49, 26.72. IR (ATR): 3310, 3269, 3072, 3033, 1655, 1644, 1583, 1544, 1509, 1425, 1325, 1314, 1260, 1168, 1116, 1070, 1015, 986, 914, 858, 777, 765, 743, 693, 644, 629 cm−1. Elemental analysis for C11H12F3N3O2 (275.23); calculated: C, 48.00; H, 4.39; N, 15.27, found: C, 47.99; H, 4.31; N, 15.33.
N-Tridecyl-2-{2-[4-(trifluoromethyl)phenyl]acetyl}hydrazine-1-carboxamide 3b. White solid. Yield 25% (method B), mp 154–156 °C. 1H NMR (500 MHz, DMSO-D6) δ 9.77 (1H, s, NH), 7.71 (1H, s, NH), 7.65 (2H, d, J = 7.9 Hz, H3, H5), 7.51 (2H, d, J = 7.9 Hz, H2, H6), 6.29 (1H, t, J = 5.8 Hz, NH-CH2), 3.55 (2H, s, CH2), 2.97 (2H, q, J = 6.6 Hz, NH-CH2), 1.34 (2H, p, J = 7.4 Hz, C2H2), 1.26–1.20 (20H, m, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.84 (3H, t, J = 6.8 Hz, CH3). 13C NMR (126 MHz, DMSO-D6) δ 169.42, 158.13, 140.86, 130.15, 127.42 (q, J = 31.8 Hz), 125.14 (q, J = 4.0 Hz), 124.56 (q, J = 271.9 Hz), 40.03, 37.48, 31.47, 30.00, 29.24, 29.22, 29.20, 29.01, 28.89, 26.47, 22.27, 14.10. IR (ATR): 3311, 2950, 2918, 2849, 1667, 1639, 1569, 1558, 1508, 1489, 1469, 1417, 1326, 1243, 1165, 1119, 1068, 1020, 981, 873, 827, 723, 652, 644, 635, 626 cm−1. Elemental analysis for C23H36F3N3O2 (443.56); calculated: C, 62.28; H, 8.18; N, 9.47, found: C, 62.29; H, 8.10; N, 9.55.
N-Methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}hydrazine-1-carboxamide 3c. White solid. Yield 64% (method C), mp 209–210 °C (decomp.). 1H NMR (600 MHz, DMSO-D6) δ 9.69 (1H, s, NH), 8.04 (1H, s, NH), 7.99–7.91 (4H, m, H2, H3, H5, H6), 6.36 (1H, q, J = 4.6 Hz, NH-CH3), 2.47 (3H, d, J = 4.6 Hz, NH-CH3). 13C NMR (151 MHz, DMSO-D6) δ 158.61, 142.87, 133.15 (q, J = 32.1 Hz), 129.32, 126.71 (q, J = 4.4 Hz), 124.11 (q, J = 272.9 Hz), 26.74. IR (ATR): 626, 707, 762, 793, 845, 964, 1016, 1062, 1095, 1110, 1135, 1172, 1192, 1302, 1319, 1358, 1405, 1418, 1489, 1564, 1648, 3113, 3417 cm−1. Elemental analysis for C9H10F3N3O3S (297.25); calculated: C, 36.37; H, 3.39; N, 14.14, found: C, 36.49; H, 3.30; N, 14.13. Rf: 0.43.
N-Tridecyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}hydrazine-1-carboxamide 3d. White solid. Yield 96% (method C), mp 157–158 °C. 1H NMR (600 MHz, DMSO-D6) δ 9.67 (1H, s, NH), 8.02 (1H, s, NH), 7.97 (2H, d, J = 8.3 Hz, H3, H5), 7.92 (2H, d, J = 8.3 Hz, H2, H6), 6.28 (1H, t, J = 6.0 Hz, NH-CH2), 2.85 (2H, q, J = 6.8 Hz, NH-CH2), 1.22–1.13 (22H, m, C2H2, C3H2, C4H2, C5H2, C6H2, C7H2, C8H2, C9H2, C10H2, C11H2, C12H2), 0.81 (3H, t, J = 6.9 Hz, CH3). 13C NMR (151 MHz, DMSO-D6) δ 157.75, 142.92, 133.13 (q, J = 32.1 Hz), 129.36, 126.61 (q, J = 4.5 Hz), 124.11 (q, J = 272.9 Hz), 31.83, 30.16, 29.60, 29.59, 29.58, 29.57, 29.56, 29.55, 29.29, 29.24, 26.70, 22.62, 14.45. IR (ATR): 635, 717, 744, 790, 842, 892, 1018, 1065, 1094, 1111, 1142, 1161, 1172, 1316, 1330, 1406, 1471, 1489, 1549, 1636, 1655, 2850, 2917, 2955, 3342 cm−1. Elemental analysis for C21H34F3N3O3S (465.58); calculated: C, 54.18; H, 7.36; N, 9.03, found: C, 54.29; H, 7.47; N, 8.92. Rf: 0.56.

3.2. Inhibition of Acetylcholinesterase and Butyrylcholinesterase

The inhibitory activity of 1–3 for AChE and BChE was determined spectrophotometrically using modified Ellman’s method [25] to quantify them in terms of IC50 values.
The enzyme activity in the final reaction mixture (2000 µL) was 0.2 U/mL, the concentration of ATCh (or BTCh) was 40 µM, and the concentration of DTNB was 100 µM for all reactions. The investigated derivatives were dissolved in DMSO and then diluted with demineralized water (conductivity 3 μS, equipment supplier BKG Water Treatment, Hradec Králové, Czech Republic) to a concentration of 1000 µM. Five different inhibitor concentrations were used for all tested compounds in the final reaction mixture. The final concentration of DMSO was 0.2%. All experiments were performed in triplicate. The average values of the reaction rate (v0-uninhibited reaction, vi-inhibited reaction) were used to construct the dependence of v0/vi on the concentration of inhibitors. IC50 values were calculated from obtained regression curve equations.
Acetylcholinesterase originating from electric eels (Electrophorus electricus L.; EeAChE) and butyrylcholinesterase obtained from equine serum (EqBChE) were used. The clinically used drug rivastigmine was involved as a reference dual AChE and BChE inhibitor. All enzymes, substrates and rivastigmine were purchased from Merck (Prague, Czech Republic).

3.3. Molecular Docking

The crystallographic structures of human AChE and human BChE were obtained from a protein data bank (www.rcsb.org, accessed on 14 December 2022; pdb codes 4PQE and 1P0I, respectively). The 3D structures of ligands were prepared in Chem3D Pro 19.1 (ChemBioOffice 2019 Package, CambridgeSoft, Cambridge, MA, USA). In the preparation process, all water molecules were removed from the enzymes, and structures of enzymes and ligands were optimized using the UCSF Chimera software package (Amber force field) [26]. Docking was performed using Autodock Vina [27] and Autodock 4.2 [28] (a Lamarckian genetic algorithm was used). The 3D affinity grid box was designed to include the full active and peripheral site of AChE and BChE. The number of grid points in the x-, y- and z-axes was 20, 20 and 20, with grid points separated by 1 Å (Autodock Vina), and 40, 40 and 40, with grid points separated by 0.4 Å (Autodock 4). The flexibility of several protein side chains was allowed. Graphic visualizations of ligand–enzyme interactions were prepared in PyMOL (The PyMOL Molecular Graphics System, Version 1.5 Schrödinger, LLC).

4. Conclusions

A series of forty-eight N-methyl/tridecyl-2-aryloylhydrazine-1-carboxamides and their analogs were designed, synthesized, characterized and investigated as potential inhibitors of acetylcholinesterase and butyrylcholinesterase. Almost all of them exhibited the dual inhibition of both cholinesterases, with IC50 values in the micromolar range. Their activity against AChE was generally higher than that against BChE, with a narrower range of IC50 values. Some of them achieved better or fairly comparable IC50 values to the drug rivastigmine. Molecular docking showed details of the molecular interactions of inhibitors with enzymes that differed for AChE and BChE. 2-(4-Nitrobenzoyl)-N-tridecylhydrazine-1-carboxamide was identified as the most promising molecule in terms of the inhibition of both enzymes at low concentrations and lipophilicity.
Further biological activity (especially antimicrobial and anticancer) will be investigated in the near future.

Author Contributions

Conceptualization, M.K.; methodology, N.-H.H., Š.Š., V.P., M.Š. and M.K.; investigation, N.-H.H., V.P., Š.Š., K.S., M.Š. and M.K.; writing—original draft preparation, N.-H.H., V.P., Š.Š., M.Š. and M.K.; writing—review and editing, Š.Š., M.Š., J.V. and M.K.; supervision, Š.Š., J.V. and M.K.; funding acquisition, J.V. and M.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Czech Science Foundation [grant number 20-19638Y] and EFSA-CDN [grant No. CZ.02.1.01/0.0/0.0/16_019/0000841] co-funded by ERDF and SVV 260 547.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Patel, S.R.; Gangwal, R.; Sangamwar, A.T.; Jain, R. Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents. Eur. J. Med. Chem. 2014, 85, 255–267. [Google Scholar] [CrossRef] [PubMed]
  2. Krátký, M.; Baranyai, Z.; Štěpánková, Š.; Svrčková, K.; Švarcová, M.; Stolaříková, J.; Horváth, L.; Bősze, S.; Vinšová, J. N-Alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides and Their Analogues: Synthesis and Multitarget Biological Activity. Molecules 2020, 10, 2268. [Google Scholar]
  3. Kumar, R.S.; Arif, I.A.; Ahamed, A.; Idhayadhulla, A. Anti-inflammatory and antimicrobial activities of novel pyrazole analogues. Saudi J. Biol. Sci. 2016, 5, 614–662. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Han, M.İ.; İnce, U.; Gündüz, M.G.; Coşkun, G.P.; Birgül, K.; Doğan, S.D.; Küçükgüzel, Ş.G. Synthesis, antimicrobial evaluation and molecular modeling studies of novel thiosemicarbazides/semicarbazides derived from p-aminobenzoic acid. J. Mol. Struct. 2022, 1261, 132907. [Google Scholar]
  5. Qin, J.; Liu, J.; Wu, C.; Xu, J.; Tang, B.; Guo, K.; Chen, X.; Liu, W.; Wu, T.; Zhou, H.; et al. Synthesis and biological evaluation of (3/4-(pyrimidin-2-ylamino)benzoyl)-based hydrazine-1-carboxamide/carbothioamide derivatives as novel RXRα antagonists. J. Enzyme Inhib. Med. Chem. 2020, 35, 880–896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Chelamalla, R.; Makula, A.; Manda, S. Design, Synthesis and in silico Studies of New 5-substituted-2-(2-(5-aryl-1H-1,2,4-triazole-3-ylthio) acetyl) Hydrazine Carbothioamide/ Carboxamides for Anticonvulsant Activity. Lett. Drug Des. Discov. 2017, 14, 1155–1163. [Google Scholar]
  7. Sharma, P.; Tripathi, A.; Tripathi, P.N.; Singh, S.S.; Singh, S.P.; Shrivastava, S.K. Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer’s Disease. ACS Chem. Neurosci. 2019, 10, 4361–4384. [Google Scholar] [CrossRef]
  8. Matošević, A.; Knežević, A.; Zandona, A.; Maraković, N.; Kovarik, Z.; Bosak, A. Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease. Pharmaceuticals 2022, 15, 1220. [Google Scholar] [CrossRef] [PubMed]
  9. Blanc, P. Acute Responses to Toxic Exposures. In Murray and Nadel’s Textbook of Respiratory Medicine, 6th ed.; Elsevier: Philadelphia, PA, USA, 2016; pp. 1343–1353.e7. [Google Scholar]
  10. Ayral-Kaloustian, S.; Mansour, T.S.; Tsou, H.-R.; Zhang, N.; Venkatesan, A.M.; Di, L.; Kerns, E.H. 3-Substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds, their use as mTOR kinase and pi3 kinase inhibitors, and their syntheses. U.S. Patent 12/556,833, 11 March 2010. [Google Scholar]
  11. Radic, Z.; Pickering, N.A.; Vellom, D.C.; Camp, S.; Taylor, P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993, 32, 12074–12084. [Google Scholar]
  12. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P.H.; Silman, I.; Sussman, J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA 1993, 90, 9031–9035. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Harel, M.; Sonoda, L.K.; Silman, I.; Sussman, J.L.; Rosenberry, T.L. Crystal structure of thioflavin T bound to the peripheral site of Torpedo californica acetylcholinesterase reveals how thioflavin T acts as a sensitive fluorescent reporter of ligand binding to the acylation site. J. Am. Chem. Soc. 2008, 130, 7856–7861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Rosenberry, T.L.; Brazzolotto, X.; Macdonald, I.R.; Wandhammer, M.; Trovaslet-Leroy, M.; Darvesh, S.; Nachon, F. Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study. Molecules 2017, 22, 2098. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Krátký, M.; Štěpánková, Š.; Brablíková, M.; Svrčková, K.; Švarcová, M.; Vinšová, J. Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2020, 20, 2106–2117. [Google Scholar] [PubMed]
  16. Popiołek, Ł.; Biernasiuk, A. Design, synthesis, and in vitro antimicrobial activity of hydrazide–hydrazones of 2-substituted acetic acid. Chem. Biol. Drug. Des. 2016, 88, 873–883. [Google Scholar] [CrossRef] [PubMed]
  17. Rodrigues, D.A.; Guerra, F.S.; Sagrillo, F.S.; Pinheiro, P.S.M.; Alves, M.A.; Thota, S.; Chaves, L.S.; Sant’Anna, C.M.R.; Fernandes, P.D.; Fraga, C.A.M. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem 2020, 15, 539–551. [Google Scholar] [CrossRef] [PubMed]
  18. Ibrahim, T.S.; Taher, E.S.; Samir, E.; Malebari, A.M.; Khayyat, A.N.; Mohamed, M.F.A.; Bokhtia, R.M.; AlAwadh, M.A.; Seliem, I.A.; Asfour, H.Z.; et al. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors. Molecules 2020, 25, 3125. [Google Scholar]
  19. Haranahalli, K.; Lazzarini, C.; Sun, Y.; Zambito, J.; Pathiranage, S.; McCarthy, J.B.; Mallamo, J.; Del Poeta, M.; Ojima, I. SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents. J. Med. Chem. 2019, 62, 8249–8273. [Google Scholar]
  20. Murty, M.S.R.; Penthala, R.; Polepalli, S.; Jain, N. Synthesis and biological evaluation of novel resveratrol-oxadiazole hybrid heterocycles as potential antiproliferative agents. Med. Chem. Res. 2016, 25, 627–643. [Google Scholar] [CrossRef]
  21. Kahl, D.J.; Hutchings, K.M.; Lisabeth, E.M.; Haak, A.J.; Leipprandt, J.R.; Dexheimer, T.; Khanna, D.; Tsou, P.-S.; Campbell, P.L.; Fox, D.A.; et al. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. J. Med. Chem. 2019, 62, 4350–4369. [Google Scholar]
  22. Takaoka, Y.; Tsutsumi, H.; Kasagi, N.; Nakata, E.; Hamachi, I. One-Pot and Sequential Organic Chemistry on an Enzyme Surface to Tether a Fluorescent Probe at the Proximity of the Active Site with Restoring Enzyme Activity. J. Am. Chem. Soc. 2006, 128, 3273–3280. [Google Scholar] [PubMed]
  23. Sakurai, M.; Kawakami, R.; Kihara, N. TBSOTf-promoted versatile N-formylation using DMF at room temperature. Tetrahedron Lett. 2019, 60, 1291–1294. [Google Scholar] [CrossRef]
  24. Zhao, X.; Zhang, L.; Li, T.; Liu, G.; Wang, H.; Lu, K. p-Toluenesulphonic acid-promoted, I2-catalysed sulphenylation of pyrazolones with aryl sulphonyl hydrazides. Chem. Commun. 2014, 50, 13121–13123. [Google Scholar]
  25. Zdrazilova, P.; Stepankova, S.; Komers, K.; Ventura, K.; Cegan, A. Half-inhibition concentrations of new cholinesterase inhibitors. Z. Naturforsch. C 2004, 59, 293–296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [Green Version]
Pharmaceuticals 16 00172 g001 550
Figure 1. Design of novel cholinesterase inhibitors.
Figure 1. Design of novel cholinesterase inhibitors.
Pharmaceuticals 16 00172 g001
Pharmaceuticals 16 00172 sch001 550
Scheme 1. Synthesis of benzohydrazides.
Scheme 1. Synthesis of benzohydrazides.
Pharmaceuticals 16 00172 sch001
Pharmaceuticals 16 00172 sch002 550
Scheme 2. Synthesis of N-methyl/tridecyl-2-benzoylhydrazine-1-carboxamides 1–2 (n = 0 or 12, R = H, 4-F, 4-Cl, 2-/3-/4-Br, 4-I, 2-/3-CF3, 4-OH, 4-Me, 4-Ph, 4-t-Bu, 4-OMe, 2-/3-/4-NO2, 4-(CH3)2N; DIPEA = N,N-diisopropylethylamine).
Scheme 2. Synthesis of N-methyl/tridecyl-2-benzoylhydrazine-1-carboxamides 1–2 (n = 0 or 12, R = H, 4-F, 4-Cl, 2-/3-/4-Br, 4-I, 2-/3-CF3, 4-OH, 4-Me, 4-Ph, 4-t-Bu, 4-OMe, 2-/3-/4-NO2, 4-(CH3)2N; DIPEA = N,N-diisopropylethylamine).
Pharmaceuticals 16 00172 sch002
Pharmaceuticals 16 00172 sch003 550
Scheme 3. Synthesis of N-methyl/tridecylhydrazine-1-carboxamides 1–3 using Curtius rearrangement (R = 3-NO2, 4-CN, 4-OCF3, 2-/3-/4-CF3, 4-OPh, 4-SO2NH2; R1 = CH3 or CH2(CH2)11CH3; X = CO, SO2).
Scheme 3. Synthesis of N-methyl/tridecylhydrazine-1-carboxamides 1–3 using Curtius rearrangement (R = 3-NO2, 4-CN, 4-OCF3, 2-/3-/4-CF3, 4-OPh, 4-SO2NH2; R1 = CH3 or CH2(CH2)11CH3; X = CO, SO2).
Pharmaceuticals 16 00172 sch003
Pharmaceuticals 16 00172 g002 550
Figure 2. Conformation of 1e (green) and 2j (cyan) in the active site of AChE and surrounding amino acid residues.
Figure 2. Conformation of 1e (green) and 2j (cyan) in the active site of AChE and surrounding amino acid residues.
Pharmaceuticals 16 00172 g002
Pharmaceuticals 16 00172 g003 550
Figure 3. Conformation of compounds 1h (yellow) and 1l (green) in BChE.
Figure 3. Conformation of compounds 1h (yellow) and 1l (green) in BChE.
Pharmaceuticals 16 00172 g003
Table
Table 1. Comparison of yields of different synthetic methods.
Table 1. Comparison of yields of different synthetic methods.
MethodYields [%]
A (MIC substitute)17–65
B (amine + triphosgene)21–84
C (Curtius rearrangement)64–99
Table
Table 2. Inhibition of AChE and BChE, selectivity indexes and lipophilicity of hydrazinecarboxamides 1–3.
Table 2. Inhibition of AChE and BChE, selectivity indexes and lipophilicity of hydrazinecarboxamides 1–3.
Pharmaceuticals 16 00172 i001
CodeRnIC50 AChE [µM]IC50 BChE [µM]Selectivity BChE/AChElogP o/w
P14-CF3031.23 ± 1.8784.16 ± 2.102.71.69
P24-CF31228.90 ± 0.67277.48 ± 10.279.65.87
Series 1: replacing 4-CF3 group
1a4-OCF3056.76 ± 0.49204.25 ± 13.513.61.49
1b4-OCF31265.14 ± 1.15125.23 ± 1.171.95.84
1c4-F057.23 ± 1.66366.27 ± 78.436.40.82
1d4-F1260.16 ± 0.53483.50 ± 20.198.05.25
1e4-Cl044.08 ± 1.79319.49 ± 12.647.21.18
1f4-Cl1286.59 ± 0.2988.68 ± 3.281.05.54
1g4-Br050.60 ± 1.55359.58 ± 2.177.11.27
1h4-Br1272.66 ± 0.6727.08 ± 0.070.45.56
1i4-I073.76 ± 1.78>500>6.81.28
1j4-I1279.73 ± 2.08192.08 ± 3.452.45.59
1k4-NO2053.99 ± 2.21177.78 ± 9.133.30.07
1l4-NO21253.69 ± 1.2022.31 ± 0.090.44.29
1m4-CN055.64 ± 0.27447.92 ± 39.038.10.36
1n4-CN1254.59 ± 1.27417.57 ± 15.727.64.66
1o4-Me062.29 ± 0.56284.42 ± 13.164.60.98
1p4-Me12100.08 ± 2.10277.38 ± 6.502.85.16
1q4-t-Bu059.97 ± 2.47281.35 ± 7.794.71.85
1r4-t-Bu1275.25 ± 0.4357.24 ± 0.230.86.12
1s4-Ph064.42 ± 1.67301.34 ± 7.464.72.03
1t4-Ph1251.14 ± 0.9832.10 ± 0.180.66.26
1u4-OMe057.16 ± 0.92170.62 ± 8.363.00.63
1v4-OMe1283.63 ± 3.16376.22 ± 17.004.54.88
1w4-OPh074.99 ± 0.84302.31 ± 2.114.01.72
1x4-OPh1258.29 ± 3.29367.76 ± 14.286.36.11
1y4-NMe2070.03 ± 1.74299.89 ± 13.644.30.68
1z4-NMe21287.67 ± 0.83188.33 ± 2.222.14.87
1aa4-OH067.57 ± 1.30247.03 ± 18.393.70.16
1bb4-OH1274.72 ± 3.31148.61 ± 10.732.04.41
1cc4-SO2NH2086.14 ± 0.50250.42 ± 5.222.9-0.52
1dd4-SO2NH21274.58 ± 1.12274.63 ± 10.703.73.84
1eeH063.25 ± 1.49229.21 ± 0.083.60.48
1ffH1273.40 ± 2.45234.84 ± 5.573.24.83
Series 2: positional isomers
2a3-CF3061.33 ± 1.00225.13 ± 7.843.71.83
2b3-CF31263.92 ± 0.83292.39 ± 10.674.65.97
2c2-CF3061.09 ± 0.03296.23 ± 0.874.81.45
2d2-CF31280.44 ± 2.10422.06 ± 12.405.25.97
2e3-NO2067.39 ± 1.72>500>7.40.02
2f3-NO21262.46 ± 1.79236.33 ± 6.543.84.31
2g2-NO2064.32 ± 2.23191.41 ± 10.083.0−0.24
2h2-NO21254.88 ± 1.08>500>9.14.29
2i3-Br051.86 ± 2.00353.80 ± 8.796.81.25
2j3-Br1244.34 ± 0.10>500>11.35.49
2k2-Br059.40 ± 1.83>500>8.41.05
2l2-Br1253.99 ± 0.44>500>9.35.50
Series 3: modification of the linker
Pharmaceuticals 16 00172 i002
3aCH2CO068.51 ± 0.25131.04 ± 9.701.91.74
3bCH2CO1281.69 ± 0.45292.90 ± 1.723.65.98
3cSO2071.14 ± 0.94424.74 ± 13.227.01.26
3dSO21258.78 ± 0.96338.98 ± 11.568.55.46
Rivastigmine56.10 ± 1.4138.40 ± 1.97-0.7
IC50 values are expressed as the mean ± SD from three independent experiments. The lowest IC50 values for each enzyme are given in bold as well as the most selective inhibitors for both enzymes.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Houngbedji, N.-H.; Štěpánková, Š.; Pflégr, V.; Svrčková, K.; Švarcová, M.; Vinšová, J.; Krátký, M. Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study. Pharmaceuticals 2023, 16, 172. https://doi.org/10.3390/ph16020172

AMA Style

Houngbedji N-H, Štěpánková Š, Pflégr V, Svrčková K, Švarcová M, Vinšová J, Krátký M. Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study. Pharmaceuticals. 2023; 16(2):172. https://doi.org/10.3390/ph16020172

Chicago/Turabian Style

Houngbedji, Neto-Honorius, Šárka Štěpánková, Václav Pflégr, Katarína Svrčková, Markéta Švarcová, Jarmila Vinšová, and Martin Krátký. 2023. "Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study" Pharmaceuticals 16, no. 2: 172. https://doi.org/10.3390/ph16020172

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop